Overview

To Evaluate the Pharmacokinetics and Safety of AD-208

Status:
Completed
Trial end date:
2020-05-04
Target enrollment:
Participant gender:
Summary
To evaluate pharmacokinetics and safety of AD-208.
Phase:
Phase 1
Details
Lead Sponsor:
Addpharma Inc.
Treatments:
Dutasteride